IBT
RVNC

International Biotechnology Trust’s Revance Therapeutics, Inc. RVNC Stock Holding History

International Biotechnology Trust’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.31M Hold
288,726
– – 1.11% 25
2023
Q2 		$7.3M Buy
288,726
+105,726
+58% +$3.29M 2.22% 15
2023
Q1 		$5.89M Buy
183,000
+63,000
+53% +$1.96M 1.64% 22
2022
Q4 		$2.21M Hold
120,000
– – 0.68% 34
2022
Q3 		$3.24M Buy
+120,000
New +$2.43M 1.04% 28

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

International Biotechnology Trust's RVNC Position: Q3 2023 in Review

International Biotechnology Trust held its Revance Therapeutics, Inc. (RVNC) position steady in Q3 2023 at 288,726 shares worth $3.31M. The position accounts for 1.11% of the portfolio, ranked #25.

International Biotechnology Trust first reported a position in RVNC in Q3 2022 and has held it in 5 quarters since. The position peaked at $7.3M in Q2 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • International Biotechnology Trust held 288,726 shares of Revance Therapeutics, Inc. worth $3.31M as of Q3 2023.
  • International Biotechnology Trust left its Revance Therapeutics, Inc. share count unchanged in Q3 2023.
  • Revance Therapeutics, Inc. made up 1.11% of International Biotechnology Trust's portfolio in Q3 2023, its #25 holding.
  • International Biotechnology Trust first reported a position in Revance Therapeutics, Inc. in Q3 2022 and has held it in 5 quarters since.
  • International Biotechnology Trust's Revance Therapeutics, Inc. position peaked at $7.3M in Q2 2023.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.